Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADG106 and Nivolumab in Metastatic NSCLC (ADIVO Lung)
NCT05236608Phase 2Unknown
- Sponsor
- National University Hospital
- Start
- Nov 2021
- Primary completion
- May 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ADG106 in non-small cell lung cancer (NSCLC), sponsored by National University Hospital. Status: unknown.
02
Drugs
ADG106
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05236608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05236608.